Printer Friendly

VERIDIEN EXPECTS FDA APPROVAL SOON ON HIV VIRUS-KILLING STERIHOL(TM)

 ST. PETERSBURG, Fla., Dec. 15 /PRNewswire/ -- Veridien Corporation (OTC Bulletin Board: VERD) said today that it expects the U.S. Food and Drug Administration (FDA) to act soon on the company's request to market Sterihol(TM), a fast-acting sterilant that destroys all forms of microbes, including the AIDS virus.
 W. Richard Clark, Veridien's chief executive officer, said the company recently filed a full and complete response to the FDA's most recent questions about Sterihol(TM). "We believe we have provided all the data required by the FDA to approve our product for public use," Clark said, "and we hope to get the FDA's okay no later than the first quarter of 1993."
 Veridien began the FDA approval process in September 1991. Clark said laboratory tests proved that Sterihol(TM) "is a faster-acting sterilant than other products on the market." He said it will destroy all pathogenic organisms, including spores, in only 10 minutes, compared to the 10 hours required by competing products. Clark said the tests show that Sterihol(TM) is effective against the AIDS-causing HIV virus in about one minute. The sterilant should prove highly popular with dentists, physicians and other healthcare professionals, he added.
 Veridien Corporation is a healthcare company specializing in developing infection control products that are highly effective, easy to use and are non-hazardous to workers and the environment.
 -0- 12/15/92
 /CONTACT: Paul L. Simmons, chairman of the board or D. Jerry Diamond, chief operating officer of Veridien Corporation, 813-572-6636 or Investor Relations Consultants, Inc., 813-796-1452/
 (VERD)


CO: Veridien Corporation ST: Florida IN: HEA MTC SU: PDT

JB -- FL002 -- 7058 12/15/92 09:04 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 15, 1992
Words:272
Previous Article:HAUSER REPORTS REVENUES AND EARNINGS DOUBLED FOR SECOND QUARTER OF FISCAL 1993
Next Article:AAA MEMBERS RECEIVE ENHANCED CAR RENTAL BENEFITS THROUGH EXCLUSIVE HERTZ PACT
Topics:


Related Articles
DISEASE DETECTION INTERNATIONAL FILES 'IND' APPLICATION WITH FDA SEEKING APPROVAL TO BEGIN FORMAL CLINICAL STUDIES FOR SEVEN-MINUTE AIDS TEST
TECHNICAL CHEMICALS AND PRODUCTS, INC. ANNOUNCES RESULTS OF CLINICAL HIV STUDIES
NEW AIDS SCREENING TEST DETECTS VIRUS EARLIER Coulter to Offer Blood and Plasma Collection Centers p24 Antigen Assay
NEW AIDS SCREENING TEST DETECTS VIRUS EARLIER; NOW AVAILABLE TO BLOOD AND PLASMA COLLECTION CENTERS
BIOCONTROL SUBSIDIARY BEGINS ADVANCED STUDIES OF AIDS TREATMENT
Visible Genetics Submits TRUGENE(TM) HIV-1 Genotyping Kit Application to The FDA.
FDA approves HIV-1/HCV assay. (New Tests).
FDA Accepts IND for Procleix(R) West Nile Virus Assay; Test Expected to be Available for U.S. Mosquito Season.
Gen-Probe Provides Update on Regulatory Status of Investigational PROCLEIX(R) ULTRIO(TM) Assay.
Calypte Begins U.S. Initiative.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters